We are pleased to announce our latest news to you.
patient2site: Technology combined with unmatched patient engagement services to create successful patient recruitment strategies, trial awareness and boost enrollment.
We take immense pride in being recognized by BioNTech SE for having been part of the unprecedented "project lightspeed" that eventually brought the first evidence-based and approved COVID-19 vaccine to the global population.
Partnership Between admedicum and IEXP To Involve Patients In All Phases Of Clinical Trials For Drug Development
The Institute of Patient Experience - IEXP - and admedicum, join forces to expand in Spain and Latin America and help conduct patient-centered trials to decrease dropout rates in clinical studies.
admedicum Business for Patients, a patient engagement expert consulting company, today announced their strategic expansion into the Netherlands and strengthening their leadership team.
Roundtable summary: Decentralized trials and the collection of routine practice data for the drug benefit assessment
Aparito and admedicum co-organised a roundtable with ten participants from the sector to discuss how decentralised trials can effectively collect data. Read the full summary.
Announcing the Launch of the European Alliance for Newborn Screening in Spinal Muscular Atrophy (SMA NBS Alliance): Opening a new horizon for children born with SMA
Patient engagement in 2030: how can patient engagement contribute towards building a new ecosystem for drug development and therapy
Patient engagement in 2030: how can patient engagement contribute towards building a new ecosystem for drug development and therapy will be held on 3 December 2020 in Amsterdam with Holland BIO. Save the date and looking forward to seeing you.
admedicum met with Joachim Sproß, managing director of the German Society for Muscular Diseases, to talk about the challenges that the corona crisis poses for patients and self-help.
How companies can contact patients and patient organizations in a compliant and mutually beneficial way
After evaluating and identifying the right patient representatives and assessing the regulatory framework conditions some companies may still struggle with a question that may sound simple but can be really tricky when it comes to acting: How to approach a patient or a patient organization in the best way?